Stay updated on Subcutaneous Atezolizumab in NSCLC Clinical Trial
Sign up to get notified when there's something new on the Subcutaneous Atezolizumab in NSCLC Clinical Trial page.

Latest updates to the Subcutaneous Atezolizumab in NSCLC Clinical Trial page
- CheckyesterdayChange DetectedA new government funding notice was added and the recruitment status was updated to Active, not recruiting (revision v3.4.1, 2026-01-29). Earlier statuses such as insufficient accrual and Terminated were removed (revision v3.4.0, 2025-08-06).SummaryDifference2%

- Check8 days agoChange DetectedShow glossary option added and color-coded change legends introduced with explanatory text; revision notes moved to v3.4.0 (removing v3.3.4) and the No FEAR Act label capitalization updated.SummaryDifference1%

- Check15 days agoNo Change Detected
- Check22 days agoChange DetectedRevision: v3.3.4 was added and Revision: v3.3.3 was removed from the Record History.SummaryDifference0.1%

- Check44 days agoChange DetectedA new site revision entry Revision: v3.3.3 was added. The items 'HHS Vulnerability Disclosure' and 'Revision: v3.3.2' were removed.SummaryDifference0.2%

- Check65 days agoChange DetectedThe Record History shows an addition of Revision: v3.3.2 and a deletion of Revision: v3.3.1 in the study record history. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.1%

- Check72 days agoChange DetectedAdded a new history entry: Revision v3.3.1. The previous Revision v3.2.0 entry has been removed.SummaryDifference0.1%

Stay in the know with updates to Subcutaneous Atezolizumab in NSCLC Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Subcutaneous Atezolizumab in NSCLC Clinical Trial page.